Company / Total Assets
NEKTAR THERAPEUTICS Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$280.4M
FY2025
5-year range
$280.4M / $1.1B
FY2021-FY2025
Trend
-7.7%
vs FY2024
Sector context
#184 of 214
Health Care
What the data says
NEKTAR THERAPEUTICS's total assets of $280M is lower than 86% of companies in the Health Care sector (FY2025). Total Assets has declined for 7 consecutive years, from $2.2B in FY2018 to $280M in FY2025.
Based on SEC 10-K filings.
$280M in FY2025 with a 5-year CAGR of -28.9%.
Declined from $398M to $280M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -26.7%
- 5-Year CAGR
- -28.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 214This company $280.4M Sector average $7.5B
▼
-96.2% below sector average
Key checks
Key Insights
- NEKTAR THERAPEUTICS's total assets has declined for 7 consecutive years.
- 5-year CAGR of -28.9%, indicating a declining trend.
- In FY2025, total assets decreased 7.7% year-over-year.
- Ranks #184 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $280.4M | -7.7% |
| FY2024 | $303.9M | -23.7% |
| FY2023 | $398.0M | -44.0% |
| FY2022 | $710.6M | -36.4% |
| FY2021 | $1.1B | -27.4% |
| FY2020 | $1.5B | -22.2% |
| FY2019 | $2.0B | -8.0% |
| FY2018 | $2.2B | +322.5% |
| FY2017 | $508.9M | -10.5% |
| FY2016 | $568.9M | +14.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026